Bruce D. Cheson
Cancer Therapy Evaluation Program
Division of Cancer Diagnosis and Treatment
National Cancer Institute
Bethesda
USA
Name/email consistency: high
- Rituximab: clinical development and future directions. Cheson, B.D. Expert. Opin. Biol. Ther (2002)
- Bexxar (Corixa/GlaxoSmithKline). Cheson, B. Curr. Opin. Investig. Drugs (2002)
- New drug development in non-Hodgkin lymphomas. Cheson, B.D. Curr. Oncol. Rep (2001)
- Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. Cheson, B.D., Horning, S.J., Coiffier, B., Shipp, M.A., Fisher, R.I., Connors, J.M., Lister, T.A., Vose, J., Grillo-López, A., Hagenbeek, A., Cabanillas, F., Klippensten, D., Hiddemann, W., Castellino, R., Harris, N.L., Armitage, J.O., Carter, W., Hoppe, R., Canellos, G.P. J. Clin. Oncol. (1999)
- Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. Cheson, B.D., Vena, D.A., Barrett, J., Freidlin, B. J. Clin. Oncol. (1999)
- Tumor lysis syndrome: an uncommon complication of fludarabine therapy of chronic lymphocytic leukemia. Cheson, B.D., Frame, J.N., Vena, D., Quashu, N., Sorensen, J.M. J. Clin. Oncol. (1998)









